10 Vegetables In Your Daily Indian Diet That Will Help You Get A Flat Belly
A flat belly is often the result of smart dietary choices rather than just exercise. Including vegetables that are rich in fibre, water, and antioxidants can help reduce bloating, improve digestion, and burn fat more effectively. In India, we are fortunate to have access to a variety of seasonal, local vegetables that support weight loss and overall health. Focus on seasonal, home-cooked meals with minimal oil and spices. Combined with regular exercise, proper hydration, and sleep, these vegetables can support your journey to a flatter, healthier belly. Here are some easily available Indian vegetables to include in your daily meals for a flatter tummy.
Also Read: Drink This Vegetable Juice Every Morning To Lose Belly Fat Faster
Here Are 10 Vegetables That Help You Lose Weight:
1. Lauki (Bottle Gourd)
Lauki is one of the best vegetables for reducing belly fat. High in water content and low in calories, it helps keep you full without overeating. It also supports digestion and acts as a mild diuretic, flushing out toxins. Lauki juice in the morning is especially popular for weight loss.
2. Palak (Spinach)
Spinach is a powerhouse of iron, fibre, and magnesium. It improves digestion, supports metabolism, and helps reduce water retention in the body. You can prepare palak sabzi, palak dal, or add it to smoothies and soups.
3. Patta Gobhi (Cabbage)
Commonly used in Indian kitchens, cabbage is low in calories and rich in fibre. It helps prevent constipation and bloating while supporting fat metabolism. Try it in sabzis, stir-fries, or cabbage parathas.
4. Bhindi (Ladyfinger/Okra)
Bhindi is rich in soluble fibre and supports healthy digestion. It helps keep you full for longer and stabilises blood sugar levels, which is crucial for weight management. Lightly sauted bhindi with minimal oil is ideal for daily meals.
5. Karela (Bitter Gourd)
Though not everyone's favourite, karela is known for its fat-burning properties. It improves liver function, detoxifies the system, and helps reduce belly fat by lowering blood sugar and insulin levels. Try it stir-fried or as juice for best results.
Also Read: Does Drinking Green Tea Help You Get a Flat Tummy?
A weight loss diet should include healthy fruits and vegetables. Image Credit: iStock
6. Ghiya-Tori (Ridge Gourd and Sponge Gourd)
These watery vegetables are easy to digest and help reduce bloating. They're rich in fibre and antioxidants, aiding in weight loss and gut health. They also make for light and cooling sabzis, perfect for daily meals.
7. Mooli (Radish)
Mooli boosts digestion and reduces bloating due to its high fibre and water content. It is particularly beneficial when eaten raw or lightly cooked. Include it in salads, parathas, or chutneys.
8. Gajar (Carrots)
Carrots are rich in fibre, beta-carotene, and antioxidants. They help keep you full and support digestion. Eat them raw as a snack, in salads, or lightly sauted for variety.
9. Kheera (Cucumber)
Cucumber is excellent for hydration and reducing water retention. Its high water content helps flush out toxins and reduce bloating. Eat it raw, as kheera raita, or infused in water.
10. Methi (Fenugreek Leaves)
Fresh methi leaves aid in digestion and have anti-inflammatory properties. They also help manage appetite and blood sugar levels. Use them in thepla, sabzi, or dal.
Incorporating these easily available Indian vegetables into your daily meals can significantly help reduce belly fat, improve digestion, and promote overall wellness.
Advertisement
Comments
About Neha Grover Love for reading roused her writing instincts. Neha is guilty of having a deep-set fixation with anything caffeinated. When she is not pouring out her nest of thoughts onto the screen, you can see her reading while sipping on coffee.
For the latest food news, health tips and recipes, like us on Facebook or follow us on Twitter and YouTube.
Tags:
Weight Loss
Belly Fat
Vegetables
Show full article
Comments
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
an hour ago
- The Hindu
Delhi HC sets aside appointment of NCISMC chairperson
The Delhi High Court on Friday (June 6, 2025) quashed the appointment of Vaidya Jayant Yeshwant Deopujari as Chairperson of the National Commission for Indian System of Medicine, holding that he does not meet the qualification prescribed for appointment to the office. The court passed the order on two petitions filed by Ved Prakash Tyagi, former president of the erstwhile Central Council for Indian Medicine, and Dr. Raghunandan Sharma challenging the appointment of Mr. Deopujari as the chairperson of the commission (NCISMC). The Ministry of Personnel, Public Grievances, and Pensions had issued a circular on June 9, 2021, appointing Mr. Deopujari as the commission's chairperson. The petitioners have alleged that Mr. Deopujari could not be appointed as the chairperson of the commission as he does not hold a postgraduate degree, mandated under the National Commission for Indian System of Medicine Act, 2020 (NCISM Act). The court held that Mr. Deopujari possessed a PhD degree, whereas the requisite degree was an MD or any other equivalent master's degree in any discipline of the Indian System of Medicine. The PhD degree that was awarded to him by Pune University did not presuppose acquisition of a lower qualification (Master's Degree in Ayurveda), it said. Ineligible person 'We have no hesitation to hold that the expression 'Post-Graduate Degree' occurring in Section 4(2) of the NCISM Act, 2020, in the context it has been used, would mean a Master's Degree (MD) in any discipline of Indian System of Medicine, which the respondent does not possess, and, therefore, he lacks the requisite qualification for being appointed to the office in question,' the court said. Mr. Tyagi's plea said the commission was a governing body for all matters relating to education and regulation of Indian medicine in the country. 'Thus, the interests of a large number of people/students/Indian medicine practitioners shall be adversely and severely affected if an ineligible person is allowed to continue as the chairperson of such a critical statutory body,' he added. The court noted that the counsel representing the Commission has stated in the court that the process of selection and appointment of the Chairperson of the Commission has commenced. 'Accordingly, we direct that the said process shall be completed with expedition, and while conducting the process of selection, the observations made hereinabove in this judgment shall be taken into account,' the court added.
Business Standard
2 hours ago
- Business Standard
G.C Chemie Pharmie: Four Decades of Innovation and Trust in Pharmaceuticals and Nutraceuticals
India PR Distribution Mumbai (Maharashtra) [India], June 6: G.C Chemie Pharmie Pvt. Ltd. (GCCPL), a pioneer in India's pharmaceutical, nutraceutical, functional foods, and biopharmaceutical sectors, proudly celebrates over 44 years of innovation and service excellence. Founded in 1981 by visionary entrepreneur Gautam Shah, GCCPL has evolved into a globally connected and innovation-driven enterprise known for its commitment to trust, transparency, and quality. What began as an API trading and distribution firm has transformed into a diversified pharmaceutical powerhouse. GCCPL's impressive timeline of achievements includes: - 2009/2010: Acquisition of Eagle Chemical Works, establishing its own API manufacturing capabilities - 2009: Release of its first vaccine, marking a significant milestone in biopharmaceuticals - 2010/2011: Launch of its P2P division, introducing affordable medicines to the Indian market -2018: Entry into the sports nutrition space - 2022: Creation of a preventive healthcare division with a focus on gynecology and orthopedics - 2023: Establishment of a dedicated vaccine division to expand immunization solutions Driven by a mission to lead through innovative thinking and technology adoption, GCCPL delivers tailored solutions across pharmaceutical, nutraceutical, and functional food categories. The company continues to differentiate itself through its strong regulatory acumen, cutting-edge R & D, and a global network of manufacturing and distribution partners. "At GCCPL, innovation is not a buzzword--it's the foundation of our growth strategy," said Founder and Chairman Gautam Shah. "We're proud to be one of India's few private companies to bring the pneumococcal vaccine to the domestic market, second only to Pfizer." Recent product highlights include UC-II®, a patented undenatured type II collagen supplement, and Pylopass™, a breakthrough strain-based probiotic--both showcasing GCCPL's commitment to introducing clinically backed, innovative health solutions to India. With a sterling reputation for regulatory compliance, deep market research, and financial integrity--as affirmed by CRISIL's highest rating A2+ GCCPL stands as a trusted partner for businesses and healthcare providers seeking reliable, next-generation healthcare products. About G.C Chemie Pharmie Pvt. Ltd. Founded in 1981, GCCPL is an Indian-based pharmaceutical and nutraceutical company with a global footprint. Known for its reliability, innovation, and commitment to quality, GCCPL offers customized, technology-driven healthcare solutions to meet the evolving needs of today's market. The company maintains a strong presence in vaccines, preventive care, functional foods, and advanced supplements.
&w=3840&q=100)
Business Standard
2 hours ago
- Business Standard
Indian pharma market grows 7.2% in May led by chronic therapies
Indian pharma market grew 7.2% in May with strong performance in chronic therapies such as cardiac and anti-infectives, along with gains from price hikes and new launches Sanket Koul New Delhi The Indian Pharma Market (IPM) grew 7.2 per cent in May this year with almost all major therapies showing positive growth, according to market research firm Pharmarack. Data suggest that big chronic therapies such as cardiac and anti-infectives, which account for nearly 25 per cent of the overall domestic market, recorded value growth of 11.7 per cent and 7.6 per cent, respectively. On the other hand, several smaller supergroups such as urology and antineoplastics, which made up 2 per cent each of the IPM's sales value for the month, also recorded double-digit growth in May at 12.3 per cent and 11.7 per cent, said Sheetal Sapale, vice-president, commercial, Pharmarack. Data suggest that the overall value growth for the IPM in May was driven by price growth and new introductions. The IPM also reported a minuscule 0.4 per cent unit growth during the month, with the chronic segments such as antidiabetics (6.1 per cent) and cardiac (4.8 per cent) performing better than the overall market figure. Experts believe that the antidiabetic segment saw a 6.1 per cent rise in volume in May due to a key drug, empagliflozin, going off-patent, as companies launched several plain and combination medications in the segment. Growth in the moving annual turnover (MAT) for the IPM between June 2024 and May 2025 stood at 8.1 per cent, leading to a total turnover of over Rs 2.29 trillion, while volumes in the domestic market grew by 1.1 per cent. The MAT of leading therapy areas such as cardiac, gastrointestinal and anti-infectives, which constitute around 38 per cent of the pharmaceutical market, showed robust volume growth at 10.4 per cent, 9.5 per cent and 6.5 per cent, respectively. While the top 20 brands in the IPM registered modest monthly value growth in the domestic market during the month, Sun Pharma and Dr Reddy's posted significant monthly value growth at 11.2 per cent each. They were followed by Torrent Pharma and Ipca Laboratories at 10.8 per cent, and Alkem Laboratories at 10.3 per cent monthly value growth. According to Pharmarack data, GlaxoSmithKline's (GSK) antibiotic medication Augmentin and USV's anti-diabetic drug Glycomet GP continued to be the top-selling medicine brands at the MAT level, with sales worth Rs 819 crore and Rs 810 crore, respectively.
